These findings highlight the potential of CCLs as multifunctional biomarkers for CRC staging diagnosis, prognosis assessment, and targeted therapy (such as restoring CCL5/CCL21 expression or inhibiting the CCL3/CCR5 axis), providing a new direction for immune-kinase combination therapy (17). This evidence concerns the gene CCL3 and colorectal carcinoma.